Niayesh Mohebbi1,2, Maryam Taghizadeh-Ghehi2, Seyed Mehrdad Savar1,2, Siamak Abdi3, Romina Kouhsari1, Kheirollah Gholami1,2, Shahriar Nafissi4,5. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 2. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. nafisi@sina.tums.ac.ir. 5. Iranian Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran. nafisi@sina.tums.ac.ir.
Abstract
BACKGROUND: Rituximab, a chimeric human/mouse monoclonal antibody targeting CD-20 antigens, has been used recently for various rheumatological and autoimmune diseases, including autoimmune neurological disorders. OBJECTIVES: We aimed to study the frequency, seriousness, causality, and preventability of adverse drug reactions (ADRs) of rituximab in Iranian patients with autoimmune neurological diseases. METHODS: In this cross-sectional observational study, patients with autoimmune neurological diseases who had an indication for rituximab treatment were enrolled. Naranjo adverse drug reaction probability scale was used to assess the causality of ADRs, and the preventability of the ADRs was determined by P-Method. The seriousness of ADRs was also determined. RESULTS: A total of 264 ADRs were recorded from 97 patients. The Median (min-max) number of ADRs experienced by patients was 3 (1-7) events. 11.3% of patients experienced serious ADRs. 18.2% and 26.9% of ADRs were Definite and Probable, respectively. Only 5% of the ADRs were ''preventable". The most frequent ADRs were rituximab infusion-related reactions. CONCLUSION: Rituximab had an acceptable safety profile in our study patients. However, there must be certain cautions regarding the use of the medication for the elderly or patients with a compromised immune system. Timely detection and management of ADRs would also be crucial to prevent severe and permanent damages. Moreover, considering that rituximab is used as an off-label treatment for autoimmune neurological diseases, a risk-benefit assessment would be necessary before deciding on the treatment choice.
BACKGROUND: Rituximab, a chimeric human/mouse monoclonal antibody targeting CD-20 antigens, has been used recently for various rheumatological and autoimmune diseases, including autoimmune neurological disorders. OBJECTIVES: We aimed to study the frequency, seriousness, causality, and preventability of adverse drug reactions (ADRs) of rituximab in Iranian patients with autoimmune neurological diseases. METHODS: In this cross-sectional observational study, patients with autoimmune neurological diseases who had an indication for rituximab treatment were enrolled. Naranjo adverse drug reaction probability scale was used to assess the causality of ADRs, and the preventability of the ADRs was determined by P-Method. The seriousness of ADRs was also determined. RESULTS: A total of 264 ADRs were recorded from 97 patients. The Median (min-max) number of ADRs experienced by patients was 3 (1-7) events. 11.3% of patients experienced serious ADRs. 18.2% and 26.9% of ADRs were Definite and Probable, respectively. Only 5% of the ADRs were ''preventable". The most frequent ADRs were rituximab infusion-related reactions. CONCLUSION: Rituximab had an acceptable safety profile in our study patients. However, there must be certain cautions regarding the use of the medication for the elderly or patients with a compromised immune system. Timely detection and management of ADRs would also be crucial to prevent severe and permanent damages. Moreover, considering that rituximab is used as an off-label treatment for autoimmune neurological diseases, a risk-benefit assessment would be necessary before deciding on the treatment choice.
Authors: A Dos Santos; J-B Noury; S Genestet; A Nadaj-Pakleza; J Cassereau; C Baron; D Videt; L Michel; Y Pereon; S Wiertlewski; A Magot Journal: Eur J Neurol Date: 2020-07-04 Impact factor: 6.089
Authors: Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer Journal: Drug Saf Date: 2019-05 Impact factor: 5.606
Authors: Carmen Alcalá; F Gascón; F Pérez-Miralles; S Gil-Perotín; A Navarré; I Boscá; F Coret; B Casanova Journal: J Neurol Date: 2018-05-21 Impact factor: 6.682
Authors: Joerg Wendler; Gerd R Burmester; Helmut Sörensen; Andreas Krause; Constanze Richter; Hans-Peter Tony; Andrea Rubbert-Roth; Peter Bartz-Bazzanella; Siegfried Wassenberg; Iris Haug-Rost; Thomas Dörner Journal: Arthritis Res Ther Date: 2014-03-26 Impact factor: 5.156